ORGO

Organogenesis Holdings Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001661181 Biotech & Drug Discovery

$0.9350 −0.06 (−5.84%)

Oct 26 4:00 PM ET · prev $0.9930

Market cap

$132.5M

Micro cap

Consensus

Sell

0% Buy or better · 7 analysts

Median target

$2.00

+114% · range $2.00–2.00

Next earnings

Nov 5

in 9 days · EPS est. −$0.17

1 year

−78.2%

from $4.28 · Oct 27

30 days

−32.2%

from $1.38

52-week range

$0.9350–6.54

at the low

Avg volume 20D

864.5K

shares / day

Short interest

🔒 Subscribers only

Insider net

+$40.1K

2 buyers · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 1 report · latest

Balance 0 bearish · 1 bullish oldest → newest, height = score

Avg score

·High conf. 1/1 ·Next Earnings date, Nov 5, 2026

Strongest BULLISH Organogenesis published peer-reviewed RCT results showing Affinity plus standard of care significantly…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Mar 9 2 insiders buy $40.1K at $2.67
E Apr 6 FDA: Organogenesis Announces Successful FDA Meeting and Plan to…
A May 28 Truist Securities initiates
E Jul 6 FDA: Organogenesis Announces FDA Acceptance of Biologics Licens…
R Jul 27 Organogenesis published peer-reviewed RCT results showing Affinity p…
E Jul 27 FDA: Organogenesis Announces Publication of Peer-Reviewed Clini…

Signal stack

Where each data set points today.

InsidersBULLISH

2 insiders bought $40.1K at an average $2.67. No open-market sales. Price is 65% below their cost.
InstitutionsBULLISH

Q2 2026: 24 added (0 new), 10 trimmed or exited.
AnalystsBEARISH

0 of 7 rate it Buy or better. Every target is above the price.
EstimatesFALLING

Current-quarter EPS estimate −$0.120 → −$0.170 over 90 days. 0 up, 1 down in 30 days.
TrendDOWNTREND

35% below its 50-day average. New closing low $0.9350 on Oct 26.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	ADD	7,249,528	$17.6M
D. E. Shaw & Co., Inc.	ADD	2,888,313	$7.0M
GOLDMAN SACHS GROUP INC	ADD	887,399	$2.2M
CITADEL ADVISORS LLC	ADD	867,929	$2.1M
NORGES BANK	TRIM	530,900	$1.3M
UBS Group AG	ADD	358,708	$871.7K
FMR LLC	TRIM	215,615	$523.9K
RAYMOND JAMES FINANCIAL INC	ADD	186,977	$454.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts

Sell 0% rate it Buy or better

Strong Buy0Buy0Hold4Sell1Strong Sell2

12-month targets · 1 analysts

$0.9350 $2.00 $2.00 $2.00

Price is below the lowest target. Median implies +114%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 7, 2026	Truist Securities MAINTAIN	MAINTAIN	Hold
May 28, 2026	Truist Securities INITIATE	INITIATE	Hold

Insider ledger

Form 4

$40.1K

bought · 2 insiders

sold · 0 insiders

−65.0%

vs their $2.67 cost

Date	Insider	Type	Value
Mar 9, 2026	Driscoll Michael Joseph Director	BUY	$26.7K
Mar 9, 2026	Leibowitz Arthur S Director	BUY	$13.4K
Mar 1, 2026	Cavorsi Robert Vice President, Strategy	TAX W/H	$2.2K
Feb 18, 2026	Montecalvo Antonio S. Vice President, Health Policy	AWARD	11,218 sh
Feb 18, 2026	Grow Brian Chief Commercial Officer	AWARD	48,330 sh
Feb 18, 2026	Cavorsi Robert Vice President, Strategy	AWARD	16,290 sh
Feb 18, 2026	Freedman Lori Chief Admin. and Legal Officer	AWARD	42,780 sh
Feb 18, 2026	Gillheeney Gary S. President and CEO	AWARD	186,968 sh

Earnings setup

Estimates

Nov 5

reports in 9 days

−$0.17

EPS estimate, this quarter

−42%

estimate change, 90 days

0↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.120

90d

−$0.125

60d

−$0.125

30d

−$0.125

−$0.170

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.17	-$0.17–-$0.17	-36.0%	$52.1M
Next Q	-$0.14	-$0.16–-$0.11	-2800.0%	$63.0M
Current FY	🔒 Fresh data, subscribers only
Next FY	-$0.31	-$0.39–-$0.23	-12.7%	$269.7M